Compare PHUN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHUN | ANIX |
|---|---|---|
| Founded | 2009 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 88.8M |
| IPO Year | 2016 | 2013 |
| Metric | PHUN | ANIX |
|---|---|---|
| Price | $2.03 | $2.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.25 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 131.6K | 99.1K |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.36 | 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | $210,000.00 |
| Revenue This Year | $89.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $2.44 |
| 52 Week High | $3.88 | $5.46 |
| Indicator | PHUN | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 47.43 |
| Support Level | $1.79 | $2.65 |
| Resistance Level | $2.28 | $3.12 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.11 | 42.86 |
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.